 |
|
The utility of ezetimibe therapy in nonalcoholic fatty liver disease
Baek Gyu Jun, Gab Jin Cheon
Korean J Intern Med. 2019;34(2):284-285. Published online 2019 Feb 25 DOI: https://doi.org/10.3904/kjim.2019.043
|
|
Citations to this article as recorded by
 Estimation of non-alcoholic steatohepatitis (NASH) disease using clinical information based on the optimal combination of intelligent algorithms for feature selection and classification
Hamed Zamanian, Ahmad Shalbaf
Computer Methods in Biomechanics and Biomedical Engineering.2024; 27(8): 964. CrossRef Hepatoprotective Activity of Ezetimibe Against Risperidone-Induced Liver Injury in Rats
Atheer Majid Rashid Al-Juhaishi, Ahmed H. Ismael, Aziz H. Jasim, Entisar J. Al-Mukhtar
Medical Journal of Babylon.2024; 21(2): 431. CrossRef Drug repurposing: Clinical practices and regulatory pathways
K. Saranraj, P. Usha Kiran
Perspectives in Clinical Research.2024;[Epub] CrossRef Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
Veronika A. Prikhodko, Natalia N. Bezborodkina, Sergey V. Okovityi
Biomedicines.2022; 10(2): 274. CrossRef Study on the Factors Related to Cholesterol Metabolism Pathway and Non-Alcoholic Fatty Liver Disease
越 张
Advances in Clinical Medicine.2022; 12(04): 3703. CrossRef Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease
Tieshan Teng, Shuai Qiu, Yiming Zhao, Siyuan Zhao, Dequan Sun, Lingzhu Hou, Yihang Li, Ke Zhou, Xixi Yu, Changyong Yang, Yanzhang Li
International Journal of Molecular Sciences.2022; 23(14): 7841. CrossRef Disturbances in Cholesterol Homeostasis and Non-alcoholic Fatty Liver Diseases
Pooja Malhotra, Ravinder K. Gill, Seema Saksena, Waddah A. Alrefai
Frontiers in Medicine.2020;[Epub] CrossRef
|